Table 1.
Comparison between the “no-APS” group and APS group according to Sydney criteria (sAPS).
| Patient Characteristics | Overall n = 165 |
No-APS n = 141 |
sAPS n= 24 |
p-Value 1 |
|---|---|---|---|---|
| Age, median (Q1–Q3), years | 33.3 (29.9, 36.7) | 33.1 (29.8, 36.7) | 33.9 (30.6, 36.2) | 0.74 |
| Smoking history, n (%) | 47 (28) | 44 (31) | 3 (12) | 0.06 |
| Ethnic group, n (%) | 0.61 | |||
| Caucasian | 151 (92) | 128 (91) | 23 (96) | |
| Maghrebin | 8 (4.8) | 8 (5.7) | 0 (0) | |
| Afro-Caribbean | 5 (3.0) | 4 (2.8) | 1 (4.2) | |
| Asian | 1 (0.6) | 1 (0.7) | 0 (0) | |
| Body mass index, median (Q1–Q3) | 23.1 (21.0, 26.4) | 24.1 (4.5) | 24.3 (3.3) | 0.37 |
| Photosensivity, n (%) | 1 (0.6) | 1 (0.7) | 0 (0) | >0.9 |
| Joint pain, n (%) | 10 (6.1) | 6 (4.3) | 4 (17) | 0.040 |
| Acrocyanosis, n (%) | 10 (6.1) | 10 (7.1) | 0 (0) | 0.36 |
| Sicca syndrome, n (%) | 2 (1.2) | 2 (1.4) | 0 (0) | >0.9 |
| Livedo, n (%) | 10 (6.1) | 8 (5.7) | 2 (8.3) | 0.64 |
| Raynaud’s phenomenon, n (%) | 11 (6.7) | 11 (7.8) | 0 (0) | 0.37 |
| Thrombosis (arterial or venous), n (%) | 6 (3.6) | 4 (2.8) | 2 (8.3) | 0.21 |
| Gestity, n (%) | 5.00 (4.00, 6.00) | 5.00 (4.00, 6.00) | 4.00 (3.75, 6.00) | 0.16 |
| ≥6 | 60 (36) | 52 (37) | 8 (33) | |
| <6 | 105 (64) | 89 (63) | 16 (67) | |
| Pregnancy, n (%) | ||||
| Live birth | 73 (44) | 65 (46) | 8 (33) | 0.24 |
| Fetal death > 24 WG | 14 (8.5) | 12 (8.5) | 2 (8.3) | >0.9 |
| Intrauterine growth restriction | 16 (9.7) | 15 (11) | 1 (4.2) | 0.47 |
| Placental vascular pathology | 29 (18) | 25 (18) | 4 (17) | >0.9 |
| HELLP or PE | 6 (3.6) | 5 (3.5) | 1(4.2) | >0.9 |
| Recurrent pregnancy loss only | 75 (45) | 63 (45) | 12 (50) | 0.63 |
| ANA, n (%) | ||||
| ≥1/80 | 75 (45) | 60 (50) | 15 (62) | 0.11 |
| ≥1/160 | 46 (28) | 40 (33) | 6 (25) | 0.92 |
| ≥1/320 | 24 (14) | 20 (17) | 5 (21) | 0.37 |
| Subsequent pregnancy | n = 109 | n = 90 | n = 19 | |
| Live birth, n (%) | 88 (79) | 72 (80) | 16 (84) | 0.76 |
| Miscarriage, n (%) | 21 (13) | 18 (20) | 3 (16) | |
| Gestation time at delivery, median (Q1–Q3), weeks | 38 (36,39) | 39.00 (37.00, 40.00) | 38.00 (37.00, 39.00) | 0.30 |
| Treatment, n (%) | ||||
| Treatment LDA + LMWH | 64 (59) | 45 (50) | 19 (100) | <0.001 |
| Treatment LDA | 31(28) | 31 (34) | 0 | 0.19 |
| No treatment | 14 (13) | 14 (16) | 0 | 0.002 |
1 Wilcoxon rank sum test; Fisher’s exact test; Pearson’s chi-squared test. ANAs: Antinuclear antibodies; HELLP: Hemolysis, Elevated Liver enzymes and Low Platelets; LDA: Low-dose aspirin; LMWH: Low-molecular-weight heparin; PE: Pre-eclampsia; WG: Weeks of gestation.